Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 650-655

  Vanholder, R ^a   Camez, A ^b   Veys, N ^a   Van Loo, A ^a   Dhondt, A M ^a   Ringoir, S ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Laboratoires Hoechst   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LEPIRUDIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0030932656     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656028     Document Type: Article

References (41)

1. Aledort L. Inhibitors in hemophilia patients: Current status and management. Am J Hematol 1994; 47: 208-17.
2. Sánchez-Cuenca JM, Carmona E, Villanueva MJ, Aznar JA. Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 1990; 57: 897-908.
3. Fulcher CA. Immunochemistry of factor VIII:C inhibitor antibodies. Am J Med 1991; 91 (suppl 5A): 6S-8S.
4. Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII Inhibitors. In: Factor VIII Inhibitors. Hoyer LW, ed. Alan R. Liss, Inc, New York 1984; pp 73-85.
5. Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-32.
6. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind to factor VIII light chains prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-84.
7. Biggs R, Austen DEG, Denson KWE, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII: I. Antibodies which have second-order concentration graphs. Br J Haematol 1972; 23: 125-35.
8. Biggs R, Austen DEG, Denson KWE, Borrett R, Rizza CR. The mode of action of antibodies which destroy factor VIII: II. Antibodies which give complex concentration graph. Br J Haematol 1972; 23: 137-55.
9. McMillan CW. Clinical patterns of hemophilic patients who develop inhibitors. Prog Clin Biol Res 1984; 150: 31-44.
10. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao VA, Lazerson J and the Hemophilia Study Group. The natural history of factor VIII : C inhibitors in patients with hemophilia A: A National Cooperative Study. II. Observations on the initial development of factor VIII : C inhibitors. Blood 1988; 71: 344-8.
11. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
12. Leyva WH, Knutsen AP, Joist JH. Disappearance of a high responder factor VIII inhibitor in a hemophiliac with AIDS. Am J Clin Pathol 1988; 89: 414-8.
13. Ragni MV, Bontempo FA, Lewis JH. Dissappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progession to AIDS or severe ARC. Transfusion 1989; 29: 447-9.
14. Hoots K. An effect of HIV infection on factor VIII (FVIII) antibodies in hemophiliacs. Blood 1987; 70(Suppl 1): 343a (Abstr).
15. Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-9.
16. Cohen H, Mackie JI, Anagnostopoulos N, Savage GF, Machin SJ. Lupus anticoagulant, anticardiolipin antibodies and human immunodeficiency virus in haemophilia. J Clin Pathol 1989; 42: 629-33.
17. Triplett DA, Brandt JT. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Hematologic Pathology 1988; 2: 12143.
18. Love PE, Santoro SA. Antiphospholipid antibodies: amicardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-98.
19. Exner T. Some recent developments with lupus anticoagulants. Blood Coagulation and Fibrinolysis 1994; 5: 281-9.
20. Cohen AJ, Philips TM, Keffler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Int Med 1986; 104: 175-80.
21. Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost 1995; 74: 329-37.
22. Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995; 78: 1-31.
23. Triplett DA, Brandt JT, Maas RL. The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 1985; 109: 946-51.
24. Triplett DA. Laboratory diagnosis of lupus anticoagulants. Sem Thromb Haemost 1990; 16: 182-92.
25. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of ISTH. Thromb Haemost 1995; 74: 1185-90.
26. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. Am J Clin Pathol 1961; 36: 212-8.
27. Triplett DA, Brandt JT, Kaczor DJ, Schaeffer J. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-82.
28. Blanco AN, Grand BE, Pieroni G, Peñalva LB, Voto LS, Lazzari MA. Behaviour of diluted activated partial thromboplastin time in pregnant women with a lupus anticoagulant. Am J Clin Pathol 1993; 100: 99-102.
29. Thiagarajan P, Pengo V, Shapiro SS. The use of the diluted Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-74.
30. Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time: Results of the College of American Pathologists Survey Program. Arch Pathol Lab Med 1991; 115: 109-14.
31. Green D, Hougie C, Kazmier FJ, Lechner K, Mannucci PM, Rizza CR, Sultan Y. Report of the working party on acquired inhibitors of coagulation: Studies of the "Lupus Anticoagulant". Thromb Haemost 1983; 49: 144-6.
32. Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from antifactor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892-6.
33. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70: 787-93.
34. Kasper CK, Aldedort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975, 34: 869-72.
35. Blanco A, Cardozo A, Esteves G, Candela M, Perez Bianco R, Lazzari M. Antifactor VIII inhibitor and lupus anticoagulant in hemophilia. A new diagnostic problem. Thromb Haemost 1995; 73: 1995a (Abstr).
36. Foster WM, Triplett DA, Barna LK. Evaluation of 7 dilute Russell viper venom (dRVVT) kits. Lupus 1994; 3: 155a (Abstr).
37. Triplett DA. New diagnostic strategies for lupus anticoagulants and antiphospholipid antibodies. Haemostasis 1994; 24: 155-63.
38. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
39. Barrowcliffe TW, Kemball-Cook G, Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 1983; 101: 34-43.
40. Bernard Ch, Bosser C, Exquis B, Tremblet Ch, Reber G, de Moerloose Ph. Incidence of anticardiolipin antibodies in hemophiliac and non-hemophiliac patients with HIV-I antibodies. Thromb Haemost 1989; 62: 1176a (Abstr).
41. Al-Saeed A, Makris M, Malia RG, Preston FE, Greaves M. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994; 88: 845-8.